Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Factor IX Stimulator Market Assessment and Forecast – Competition Landscape, Commercial, and Pipeline Analysis, 2023-2029
Factor IX Stimulator Market Assessment and Forecast – Competition Landscape, Commercial, and Pipeline Analysis, 2023-2029
Factor IX stimulants are a class of medications used to treat hemophilia B; a genetic bleeding disorder characterized by a deficiency in clotting factor IX. These stimulants work by binding to a specific receptor on liver cells, known as the coagulation factor IX receptor, which activates signaling pathways that stimulate the production and release of factor IX. This increased production of factor IX helps in clot formation and prevents excessive bleeding. Factor IX stimulants are indicated for the management and prevention of bleeding episodes in individuals with hemophilia B, including both on-demand treatment and prophylactic therapy. Additionally, Factor IX stimulators are being investigated for their potential use in other conditions, including congenital bleeding disorder and in case of excessive menstrual flow.
According to Statista, the most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2019, there were around 195,263 people worldwide who had been diagnosed with hemophilia and 80,302 who had been diagnosed with von Willebrand disease. Companies such as Takeda, CSL Behring, Grifols, Pfizer, Bayer, Novo Nordisk, Roche, and Sanofi currently cater to the bleeding disorder segment. Moreover, many companies are coming up with new molecules in this space. For instance, Pfizer is currently conducting a clinical trial for the drug Fidanacogene elaparvovec (PF-06838435) for the treatment of Coagulation protein disorder.
Key Developments
Approved Drug Molecules for Factor IX Stimulator
Drugs under the Pipeline for Factor IX Stimulator
Clinical Activity and Development of Factor IX Stimulator
In the Factor IX stimulator space, approximately 36 companies are focusing on 345 disease indications, and more than 600 clinical trials are being conducted in this category of drugs. For instance,
|
Product Name |
Number of Studies |
|
idanacogene |
4 |
|
verbrinacogene |
4 |
|
AMT-060 |
3 |
|
BAX |
3 |
|
BBM-H901 |
3 |
|
VGB-R04 |
3 |
|
DTX101 |
2 |
|
Hemgenix |
1 |
The factor IX stimulators are primarily used to treat blood coagulation, coagulation protein, genetic diseases, genetic diseases, hematologic diseases, hemophilia B, hemostatic disorders, and hemophilia A. Factor IX stimulators also help to prevent hemorrhagic disorder. For instance, Rebinyn is one drug by Novo Nordisk which is used extensively for the treatment of hemorrhagic disorder. In the treatment of hemostatic disorders, Factor IX stimulator Ixinity is used widely. Through research and development, the indications in which Factor IX stimulators can be used are getting expanded. For instance, Factor IX stimulators are now under clinical trial for the treatment of hypersensitivity.
Download Free Sample Report
The approved molecules of Factor IX stimulators are BeneFix (nonacog alfa), Alprolix (eftrenonacog alfa), Rebinyn (nonacog beta pegol), Rixubis (nonacog gamma), Ixinity (trenonacog alfa), and Idelvion (albutrepenonacog alfa).
Two significant growth drivers of the Factor IX stimulator market are the increasing prevalence of hemophilia B, which creates a higher demand for effective treatments, and advancements in medical research and technology that have led to the development of more innovative and efficient Factor IX stimulators. Additionally, the growing awareness and initiatives to improve hemophilia care and access to treatment contribute to the market's growth.
The major players in this space are Takeda, CSL Behring, Grifols, Pfizer, Bayer, Novo Nordisk, Roche, and Sanofi
The key restraining factors of the Factor IX stimulator market are the high cost of these medications, which can limit accessibility for patients, and the potential for side effects or adverse reactions associated with their use. Additionally, the need for regular administration and monitoring of Factor IX stimulators may pose logistical challenges for patients and healthcare providers.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.